MedPath

Sanofi

Sanofi logo
🇫🇷France
Ownership
Public
Employees
87.9K
Market Cap
$141.3B
Website
http://www.sanofi.com
Introduction

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Acceptability Dermacyd Wipes - Lactoserum - Hygiene

Phase 3
Completed
Conditions
Hygiene
First Posted Date
2006-11-09
Last Posted Date
2008-05-16
Lead Sponsor
Sanofi
Target Recruit Count
30
Registration Number
NCT00397527
Locations
🇧🇷

Sanofi-Aventis, São Paulo, Brazil

Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder

Phase 3
Terminated
Conditions
Anxiety Disorders
First Posted Date
2006-11-08
Last Posted Date
2009-03-12
Lead Sponsor
Sanofi
Target Recruit Count
257
Registration Number
NCT00397098
Locations
🇪🇸

Sanofi-Aventis Administrative Office, Barcelona, Spain

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

Phase 3
Completed
Conditions
Heart Defects, Congenital
Interventions
First Posted Date
2006-11-08
Last Posted Date
2014-10-24
Lead Sponsor
Sanofi
Target Recruit Count
906
Registration Number
NCT00396877
Locations
🇨🇳

Sanofi-Aventis Administrative Office, Taipei, Taiwan

🇬🇧

Sanofi-Aventis Admnistrative Office, Guildford Surrey, United Kingdom

🇹🇭

Sanofi-Aventis Administraive Office, Bangkok, Thailand

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

Phase 2
Completed
Conditions
Ovarian Neoplasms
Interventions
First Posted Date
2006-11-07
Last Posted Date
2013-01-10
Lead Sponsor
Sanofi
Target Recruit Count
16
Registration Number
NCT00396591
Locations
🇸🇪

Sanofi-Aventis Administrative Office, Bromma, Sweden

Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children

Phase 3
Completed
Conditions
Tonsillitis
Interventions
First Posted Date
2006-10-29
Last Posted Date
2009-03-17
Lead Sponsor
Sanofi
Target Recruit Count
395
Registration Number
NCT00393744
Locations
🇫🇷

Sanofi-Aventis, Paris, France

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Phase 2
Completed
Conditions
Orthomyxoviridae Infection
Influenza
Myxovirus Infection
Interventions
Biological: Split, Inactivated, Trivalent Influenza Vaccine
Biological: Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
First Posted Date
2006-10-24
Last Posted Date
2011-12-01
Lead Sponsor
Sanofi
Target Recruit Count
520
Registration Number
NCT00391391

A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

Phase 3
Completed
Conditions
Anxiety
First Posted Date
2006-10-20
Last Posted Date
2011-04-06
Lead Sponsor
Sanofi
Target Recruit Count
366
Registration Number
NCT00390650
Locations
🇨🇦

Sanofi-Aventis, Laval, Canada

An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder

Phase 3
Completed
Conditions
Generalized Anxiety
Interventions
Drug: Saredutant
Drug: Placebo
First Posted Date
2006-10-20
Last Posted Date
2016-05-24
Lead Sponsor
Sanofi
Target Recruit Count
428
Registration Number
NCT00390533
Locations
🇦🇺

Sanofi-Aventis Administrative Office, Macquarie Park, Australia

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Phase 2
Completed
Conditions
Orthomyxoviridae Infection
Influenza
Myxovirus Infection
Interventions
Biological: Split, Inactivated, Trivalent Influenza Vaccine
First Posted Date
2006-10-17
Last Posted Date
2012-04-18
Lead Sponsor
Sanofi
Target Recruit Count
817
Registration Number
NCT00388583
© Copyright 2025. All Rights Reserved by MedPath